Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Baptista, Marco A S ^a   Dave, Kuldip D ^a   Frasier, Mark A ^a   Sherer, Todd B ^a   Greeley, Melanie ^b   Beck, Melissa J ^b   Varsho, Julie S ^b   Parker, George A ^b   Moore, Cindy ^c   Churchill, Madeline J ^c   Meshul, Charles K ^c   Fiske, Brian K ^a  

^a THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

^b WIL RESEARCH LABORATORIES   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LRRK2 PROTEIN, RAT; PROTEIN SERINE THREONINE KINASE;

ANIMAL; DEFICIENCY; KIDNEY; LIVER; LUNG; MALE; METABOLISM; MUTANT RAT STRAIN; PATHOLOGY; PHENOTYPE; RAT; SPLEEN;

ANIMALS; KIDNEY; LIVER; LUNG; MALE; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, MUTANT STRAINS; SPLEEN;

EID: 84893527711     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080705     Document Type: Article

References (27)

1. Ness D, Ren Z, Gardai S, Sharpnack D, Johnson VJ et al. (2013) Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis. PLOS ONE 8: e66164. doi:10.1371/journal.pone.0066164. PubMed: 23799078. PONE-D-13-08292 . PII.
2. Lees AJ, Hardy J, Revesz T (2009) Parkinson's disease. Lancet 373: 2055-2066. doi:10.1016/S0140-6736(09)60492-X. PubMed: 19524782.
3. Dawson TM, Moore DJ, West AB (2009) Revelations and revolutions in the understanding of Parkinson's disease. Biochim Biophys Acta 1792: 585-586. doi:10.1016/j.bbadis.2009.06.001. PubMed: 19539178.
4. Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5: 235-245. doi:10.1016/S1474-4422(06)70373-8. PubMed: 16488379. (Pubitemid 43238347)
5. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047. doi:10.1126/science.276.5321.2045. PubMed: 9197268. (Pubitemid 27443610)
6. Nussbaum RL, Polymeropoulos MH (1997) Genetics of Parkinson's disease. Hum Mol Genet 6: 1687-1691. doi:10.1093/hmg/6.10.1687. PubMed: 9300660. (Pubitemid 27401611)
7. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607. doi:10.1016/j.neuron.2004.11.005. PubMed: 15541309. (Pubitemid 39531225)
8. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354: 424-425. doi:10.1056/NEJMc055509. PubMed: 16436782. (Pubitemid 43145083)
9. Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K et al. (2007) Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord 22: 55-61. doi:10.1002/mds.21180. PubMed: 17115391. (Pubitemid 46382673)
10. Ross OA, Wu YR, Lee MC, Funayama M, Chen ML et al. (2008) Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol 64: 88-92. doi:10.1002/ana.21405. PubMed: 18412265.
11. Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11: 791-797. doi:10.1038/nrn2935. PubMed: 21088684.
12. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102: 16842-16847. doi:10.1073/pnas.0507360102. PubMed: 16269541. (Pubitemid 41688864)
13. Rudenko IN, Chia R, Cookson MR, Rudenko IN, Chia R, et al. (2012) Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Med 10: 20: 1741-7015-10-20. PubMed: 22361010. PII];10.1186/1741-7015-10-20 [doi]. PubMed: 22361010.
14. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R et al. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 107: 9879-9884. doi: 10.1073/pnas.1004676107. PubMed: 20457918.
15. Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y et al. (2012) Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener 7: 2. doi: 10.1186/1750-1326-7-2. PubMed: 22230652.
16. Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T et al. (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum: Mol Genet .
17. Hinkle KM, Yue M, Behrouz B, Dächsel JC, Lincoln SJ et al. (2012) LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol Neurodegener 7: 25. doi:10.1186/1750-1326-7-S1-L25. PubMed: 22647713.
18. Luna LG (1968) AFIP Method for Lipofuscin: Manual for Histologic Staining Methods of the Armed Forces. Institute of Pathology. 186 pp.
19. de Rijk EP, Ravesloot WT, Wijnands Y, van EE (2003) A fast histochemical staining method to identify hyaline droplets in the rat kidney. Toxicol Pathol 31: 462-464. VX2XE18QTDXJ6MME . PII.
20. Huynh KK, Eskelinen EL, Scott CC, Malevanets A, Saftig P et al. (2007) LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J 26: 313-324. doi:10.1038/sj.emboj.7601511. PubMed: 17245426. 7601511 . PII;Retrieved onpublished at whilst December year 1111 from . doi:10.1038/sj.emboj.7601511
21. Westhuyzen J, Endre ZH, Reece G, Reith DM, Saltissi D et al. (2003) Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant 18: 543-551. doi:10.1093/ndt/18.3.543. PubMed: 12584277. (Pubitemid 36305660)
22. Zhang J, Goering PL, Espandiari P, Shaw M, Bonventre JV et al. (2009) Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: potential role of iNOS and nitrotyrosine. Toxicol Pathol 37: 629-643. doi:10.1177/0192623309339605. PubMed: 19535489. 0192623309339605 . PII;Retrieved onpublished at whilst December year 1111 from . doi:10.1177/0192623309339605
23. Walker RH, Moore C, Davies G, Dirling LB, Koch RJ et al. (2012) Effects of subthalamic nucleus lesions and stimulation upon corticostriatal afferents in the 6-hydroxydopamine-lesioned rat. PLOS ONE 7: e32919. doi:10.1371/journal. pone.0032919. PubMed: 22427909. PONE-D-11-23644 . PII.
24. Hard GC, Khan KN (2004) A contemporary overview of chronic progressive nephropathy in the laboratory rat, and its significance for human risk assessment. Toxicol Pathol 32: 171-180. doi: 10.1080/01926230490422574. PubMed: 15200155. JQ0P52PF3Q195GCE . PII.
25. Loeb WF, Quimby FW (99 A.D.) The clinical chemistry of laboratory animals. 2.
26. Corder CN, Collins JG, Brannan TS, Sharma J (1977) Aldose reductase and sorbitol dehydrogenase distribution in rat kidney. J Histochem Cytochem 25: 1-8. doi:10.1177/25.1.401844. PubMed: 401844. (Pubitemid 8034870)
27. Fraser KB, Moehle MS, Daher JP, Webber PJ, Williams JY et al. (2013) LRRK2 secretion in exosomes is regulated by 14-3-3. Hum Mol Genet DDT346: ([MedlinePgn:]) PubMed: 23886663. PII];10.1093/hmg/ddt346 [doi]. PubMed: 23886663.